SRTS Stock Forecast: Sensus Healthcare, Inc. Price Predictions for 2026-2027
The 4 Wall Street analysts covering Sensus Healthcare, Inc. hold a median 12-month price target of $5.5 — +142.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 50 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Sensus Healthcare, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (77): The share price has been relatively steady.
Revisions (21): Analysts have, on balance, been cutting their forecasts.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
SRTS stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on SRTS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +142.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Aug 2026 | Lake Street | Maintains | Buy | $4.50 → $4.00 |
| 17 Feb 2026 | Maxim Group | Maintains | Buy | $8.00 → $6.00 |
| 12 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 Aug 2025 | Lake Street | Maintains | Buy | — |
| 19 May 2025 | Maxim Group | Maintains | Buy | — |
| 4 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Mar 2025 | Lake Street | Maintains | Buy | — |
| 10 Feb 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 18 Nov 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Nov 2024 | Maxim Group | Maintains | Buy | — |
| 12 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 May 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 10 May 2024 | Maxim Group | Maintains | Buy | — |
| 13 Nov 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Aug 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 4 May 2023 | Alliance Global Partners | Maintains | Buy | — |
| 4 May 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 Feb 2023 | Alliance Global Partners | Maintains | Buy | — |
| 10 Feb 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Nov 2022 | Alliance Global Partners | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for SRTS.
This page is one stock. Monday covers all of them.
SRTS appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
SRTS vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Sensus Healthcare, Inc. returned −42.2% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
SRTS analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 2.3×
- Price / book
- 1.1×
- EV / EBITDA
- —
Cheaper than 43% of US stocks
Cheaper than 67% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 33.6%
- Operating margin
- −74.0%
- Net margin
- —
Higher than 40% of US stocks
Higher than 16% of US stocks
- Return on equity
- −37.0%
- Return on assets
- −15.6%
- Dividend yield
- —
Higher than 25% of US stocks
Higher than 22% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Sensus Healthcare, Inc. has a market value of $38.9M and an enterprise value of $26.2M.
Revenue in the twelve months to 30 June 2026: $17.5M. The latest quarter shrank 68.7% year on year.
Net income over the same four quarters: −$15.5M, a −88.5% net margin.
Diluted earnings per share, trailing twelve months: −$0.94.
Free cash flow in the twelve months to 30 June 2026: −$7.0M.
Sensus Healthcare, Inc. spent $0.0 on share buybacks in the twelve months to 30 June 2026.
Sensus Healthcare, Inc. employs 60 people — $292K of revenue per employee.
Data provided by Twelve Data
SRTS and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at SRTS’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Sensus Healthcare, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about SRTS
What is the SRTS stock price forecast for 2026-2027?
The 4 Wall Street analysts covering Sensus Healthcare, Inc. have a median 12-month price target of $5.5, with estimates ranging from $4 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is SRTS stock a buy right now?
Of the 4 analysts covering Sensus Healthcare, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Sensus Healthcare, Inc. 50 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank SRTS?
As at 21 Nov 2026, Sensus Healthcare, Inc. ranks 50 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (77 of 100).
Will SRTS stock go up?
No one can know that. What the data says: the median 12-month target from 4 analysts implies +142.3% from the last close, and Ticker Nerd's factor model ranks Sensus Healthcare, Inc. 50 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the SRTS stock forecast for 2030?
No analyst covering Sensus Healthcare, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SRTS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $6 over the next 12 months.
How has SRTS stock performed over the past year?
Sensus Healthcare, Inc. returned -42.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Sensus Healthcare, Inc. do?
Sensus Healthcare Inc. is a medical device company focused on non-invasive treatments for oncological and non-oncological skin conditions. The company develops and commercializes superficial radiation therapy systems that use low-energy X-ray technology to treat conditions such as non-melanoma skin cancers and keloids.
About Sensus Healthcare, Inc.
Sensus Healthcare Inc. is a medical device company focused on non-invasive treatments for oncological and non-oncological skin conditions. The company develops and commercializes superficial radiation therapy systems that use low-energy X-ray technology to treat conditions such as non-melanoma skin cancers and keloids. Its product portfolio includes the SRT-100, SRT-100+, and SRT-100 Vision systems, along with related service and support offerings for healthcare providers. Sensus Healthcare serves dermatology and other clinical practices that seek targeted treatment options for superficial skin lesions and scar management. Based in Boca Raton, Florida, the company operates in the medical technology market with a focus on specialized radiation-based solutions for skin care applications.
CEO Mr. Joseph C. Sardano · 60 employees · United States · https://sensushealthcare.com